On 11–12 June 2019, over 60 pharma stakeholders met in Amsterdam at the 8th Annual Publication and Clinical Trial Transparency Conference to discuss the evolving landscape of clinical trial transparency.
The Good Practice for Conference Abstracts and Presentations (GPCAP) recommendations have been developed to address the challenges faced by industry professionals and authors when preparing abstracts and presentations for academic conferences.
On 15 May 2019, the Center for Biomedical Research Transparency (CBMRT) brought the stakeholders in academic publishing together to share their varying perspectives on research transparency and accessibility at the European Biomedical Transparency Summit (BMTS), in Paris.
Last week’s ISMPP-U webinar ‘Open Access and Medical Publishing’, developed by the Medical Publishing Insights & Practices (MPIP) initiative and Open Pharma and moderated by LaVerne Mooney (Pfizer) and Chris Winchester (Oxford PharmaGenesis), aimed to define the key elements of open access policies, to provide insight into the changing publishing environment and to understand the perspectives of non-commercial and commercial stakeholders on open access publishing.
In recent years, open access has provided new audiences, including patients, the general public and doctors in low and middle income countries (LMICs), with direct, free access to the results of scientific research.
In order to protect the quality of clinical research it is vital for all trials to be represented in scientific literature for the benefit of scientific progress and research efficiency, and, ultimately, to better inform care for our patients in a timely manner.
CrossRef is a nonprofit whose goal is to catalogue metadata about scholarly works in order to facilitate easier access and correct record keeping--and they might just become medical publishers’ new best friend.
Based on our experience, we believe that ORCID can make medical publishing faster and more transparent.
With CRediT, ORCID and Publons integrated into Editorial Manager®, we aim for these transparency tools to be easy, standard steps in the publishing process
Personal commentary from Richard Smith, chair of Open Pharma